Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  1998-03-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.CIR.97.8.780PMID 9498542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux*

  1997cited by this paper
• Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.

  1997cited by this paper
• Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells.

  1997cited by this paper
• Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels

  1997cited by this paper
• A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.

  1996cited by this paper
• Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

  1996cited by this paper
• Beyond LDL cholesterol reduction.

  1996cited by this paper
• Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor

  1996cited by this paper
• The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture.

  1996cited by this paper
• Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits.

  1995cited by this paper
• Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated.

  1995cited by this paper
• Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits.

  1995cited by this paper
• ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum.

  1994cited by this paper
• Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.

  1994cited by this paper
• A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer.

  1994cited by this paper
• Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

  1994cited by this paper
• Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification.

  1994cited by this paper
• Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.

  1994cited by this paper
• Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits.

  1994cited by this paper
• The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.

  1993cited by this paper
• Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events

  1993cited by this paper
• High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation.

  1993cited by this paper
• Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9.

  1993cited by this paper
• Induction of platelet-derived growth factor chain A gene expression in human smooth muscle cells by oxidized low density lipoproteins.

  1992cited by this paper
• Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

  1992cited by this paper
• Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

  1992cited by this paper
• Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells.

  1992cited by this paper
• High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors.

  1992cited by this paper
• Induction of T-cell activation by oxidized low density lipoprotein.

  1992cited by this paper
• Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.

  1992cited by this paper
• Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI

  1991cited by this paper
• Reverse cholesterol transport: physiology and pharmacology.

  1991cited by this paper
• Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

  1990cited by this paper
• Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.

  1990cited by this paper
• Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.

  1990cited by this paper
• Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937.

  1990cited by this paper
• High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein.

  1990cited by this paper
• High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

  1989cited by this paper
• High-density lipoprotein--the clinical implications of recent studies.

  1989cited by this paper
• Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man.

  1985cited by this paper
• Familial associations of lipids and lipoproteins in a highly consanguineous population: the Limone sul Garda study.

  1985cited by this paper
• Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant.

  1985cited by this paper
• AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission.

  1985cited by this paper
• Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns.

  1985cited by this paper
• A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.

  1980cited by this paper
• DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY

  1980cited by this paper
• The picomole determination of free and total cholesterol in cells in culture.

  1978cited by this paper
• The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.

  1977cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper
• Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.

  1976cited by this paper

• Apolipoprotein A1 reduces blood–spinal cord barrier leakage, improves astrocytic coverage, and enhances motor neuron survival to restore the neurovascular unit in ALS mice

  2026cites this paper
• Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management

  2025cites this paper
• High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review

  2024cites this paper
• A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

  2023cites this paper
• Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction

  2023cites this paper
• Therapeutic effect of human ApoA‐I‐Milano variant in aged transgenic mouse model of Alzheimer's disease

  2023cites this paper
• Apolipoprotein A1 Enhances Endothelial Cell Survival in an In Vitro Model of ALS

  2022cites this paper
• Peptidoglycan Recognition Protein 1 Attenuates Atherosclerosis by Suppressing Endothelial Cell Adhesion

  2021cites this paper
• Peptide-based high-density lipoprotein promotes adipose tissue browning and restrains development of atherosclerosis and type 2 diabetes

  2021cites this paper
• Genetically Modified Crops: Current Status, Prospects and Challenges Volume 2

  2021cites this paper
• Identification of Haptoglobin as a Potential Biomarker in Young Adults with Acute Myocardial Infarction by Proteomic Analysis

  2020cites this paper
• Genetic Engineering in Safflower (Carthamus tinctorius L.): Retrospect and Prospect

  2020cites this paper
• Lipid efflux mechanisms, relation to disease and potential therapeutic aspects.

  2020cites this paper
• A systematic review of the biodistribution of biomimetic high-density lipoproteins in mice.

  2020cites this paper
• Genetic Disorders of Lipoprotein Metabolism

  2020cites this paper
• ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice

  2019cites this paper
• A Compendium of the Biological Effects of Apolipoprotein A-IMilano

  2019cites this paper
• Improvement of HDL

  2019cites this paper
• Proteomic Profiles of Young Adults with Acute Myocardial Infarction

  2018cites this paper
• HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway.

  2018cites this paper
• APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe-/- atherosclerotic mice.

  2018cites this paper
• Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates

  2018cites this paper
• The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications

  2018cites this paper
• Intravenous treatment with human recombinant ApoA-I Milano reduces β-amyloid cerebral deposition in the APP 23-transgenic mouse model of Alzheimer ’ s disease

  2017cites this paper
• Klinische Bedeutung des HDL-Cholesterins

  2017cites this paper
• Theranostic nanoparticles for the management of inflammatory diseases and conditions

  2017cites this paper
• Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease.

  2017cites this paper
• HDL cholesterol: reappraisal of its clinical relevance

  2017cites this paper
• A comprehensive approach to the treatment of atherosclerosis by increased ApoA-I and HDL-cholesterol levels

  2017cites this paper
• Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.

  2016cites this paper
• therothrombosis and High-Risk Plaque art I : Evolving Concepts

  2016cites this paper
• High-Density Lipoprotein Cholesterol

  2016cites this paper
• Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?

  2016cites this paper
• New Era of Lipid-Lowering Drugs

  2016cites this paper
• apid Reversal of Endothelial ysfunction in Hypercholesterolemic polipoprotein E-Null Mice by Recombinant polipoprotein A-IMilano-Phospholipid Complex

  2016cites this paper
• Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis

  2016cites this paper
• Acute high-density lipoprotein therapies

  2015cites this paper
• Recombinant HDL (Milano) protects endotoxin-challenged rats from multiple organ injury and dysfunction

  2015cites this paper
• Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

  2015cites this paper
• ApoA-I mimetics.

  2015cites this paper
• HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis

  2015cites this paper
• The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies.

  2015cites this paper
• Comparative Antiatherogenic Effects of Intravenous AAV8- and AAV2-Mediated ApoA-IMilano Gene Transfer in Hypercholesterolemic Mice

  2015cites this paper
• High-density lipoprotein mimetics: promises and challenges.

  2015cites this paper
• Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

  2014cites this paper
• HDL Cholesterol: All Hope Is Not Lost After the Torcetrapib Setback—Emerging Therapeutic Strategies on the Horizon

  2014cites this paper
• Reconstituted high-density lipoprotein therapies: a cause for optimism.

  2014cites this paper
• Beginning to understand high-density lipoproteins.

  2014cites this paper
• Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice

  2014cites this paper
• Role of HDL in Those with Diabetes

  2014cites this paper
• Secondary Structure Changes in ApoA-I Milano (R173C) Are Not Accompanied by a Decrease in Protein Stability or Solubility

  2014cites this paper
• Apolipoprotein A-I Mutations and Clinical Evaluation

  2014cites this paper
• Regulation and transport of apolipoprotein A-I into the central nervous system and therapeutic potential in Alzheimer's disease

  2014cites this paper
• Role of HDL in those with diabetes.

  2014cites this paper
• A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation

  2014cites this paper
• Current guidelines for high-density lipoprotein cholesterol in therapy and future directions

  2014cites this paper
• L-4F Inhibits Lipopolysaccharide-Mediated Activation of Primary Human Neutrophils

  2014cites this paper
• High Density Lipoprotein: Assembly, Structure, Cargo, and Functions

  2013cites this paper
• New Methods in Cardiovascular Biology Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity

  2013cites this paper
• New Methods in Cardiovascular Biology Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity

  2013cites this paper
• Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys[S]

  2013cites this paper
• Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity

  2013cites this paper
• HDL-C: does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies.

  2013cites this paper
• Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities

  2012cites this paper
• Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?

  2012cites this paper
• Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease

  2012cites this paper
• Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties.

  2012cites this paper
• The Lipid-Bound Apolipoprotein A-I Cysteine Mutant (N74C) Inhibits the Activation of NF-κB, JNK and p38 in Endotoxemic Mice and RAW264.7 Cells

  2012cites this paper
• Plant‐Derived Manufacturing of Apolipoprotein AIMilano: Purification and Functional Characterization

  2012cites this paper
• ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice

  2012cites this paper
• Apolipoprotein A-I Modulates Processes Associated with Diet-Induced Nonalcoholic Fatty Liver Disease in Mice

  2012cites this paper
• Low High-Density Lipoprotein Cholesterol

  2012cites this paper
• Novel therapeutic approaches to prevention and regression of atherosclerosis

  2012cites this paper
• Regulation of ABCA1 functions by signaling pathways.

  2012cites this paper
• Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases.

  2012cites this paper
• Expression and purification of recombinant apolipoprotein A-I Zaragoza (L144R) and formation of reconstituted HDL particles.

  2011cites this paper
• Testosterone and cardiovascular disease: an old idea with modern clinical implications.

  2011cites this paper
• Dégradation des membres de la famille du LDLRpar la convertase PCSK9 : troisième locus de l'hypercholestérolémie familiale

  2011cites this paper
• Synthesis of recombinant high density lipoprotein with apolipoprotein A-I and apolipoprotein A-V

  2011cites this paper
• Expression and recovery of biologically active recombinant Apolipoprotein AI(Milano) from transgenic safflower (Carthamus tinctorius) seeds.

  2011cites this paper
• Conformation of Dimeric ApoA-I Milano on Recombinant Lipoprotein Particles

  2011cites this paper
• High-dose phosphatidylcholine particle mobilizes free cholesterol and rapidly stabilizes established atherosclerotic lesions

  2011cites this paper
• Emerging therapies for atherosclerosis prevention and management.

  2011cites this paper
• CETP expression reverses the reconstituted HDL-induced increase in VLDL

  2011cites this paper
• Recombinant High-Density Lipoprotein Formulations

  2011cites this paper
• Inhibition de l'athérosclérose par le biais de la modulation du phénotype des monocytes-macrophages en utilisant le transfert du gène apo a-i milano

  2011cites this paper
• Progress in HDL-Based Therapies for Atherosclerosis

  2011cites this paper
• Association of the serum apolipoprotein levels with the occurrence of coronary vasospasm

  2011cites this paper
• Novel HDL-directed pharmacotherapeutic strategies

  2011cites this paper
• Seeking novel targets for improving in vivo macrophage-specific reverse cholesterol transport: translating basic science into new therapies for the prevention and treatment of atherosclerosis.

  2011cites this paper
• Perspectives and opportunities for nanomedicine in the management of atherosclerosis

  2011cites this paper
• HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution.

  2011cites this paper
• Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

  2011cites this paper
• ETC-216 for coronary artery disease

  2011cites this paper
• The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results

  2011cites this paper
• Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles.

  2010cites this paper
• Incremento de las HDL como arma terapéutica en la aterotrombosis

  2010cites this paper
• Relevance of sphingolipids in the pleiotropic protective effects of high-density lipoproteins.

  2010cites this paper
• Oxidative Stress and Risk of Cardiovascular Disease Associated with Low- and High-Monounsaturated Fat Portfolio Diets

  2010cites this paper
• Effect in vitro of apolipoprotein A-V on the structure and functions of recombinant high density lipoprotein.

  2010cites this paper